GlassScriptPhysician profile
Joanne Arbusto
NPI 1336373224
$2,438.06
in general payments reported to CMS, 2019-2025
25 companies · $831 in 2025
The $831 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $348 · 2023: $267 · 2024: $350 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $704.66 | 2021-2025 | Belbuca, Xtampza, Nucynta |
| Scilex Pharmaceuticals INC. | $690.38 | 2021-2025 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $212.45 | 2024-2025 | Rexulti |
| Biodelivery Sciences International, INC. | $99.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.98 | 2021-2025 | Relistor, Xifaxan |
| Abbvie INC. | $78.24 | 2022-2025 | |
| Axsome Therapeutics, INC. | $70.44 | 2025 | Auvelity |
| Lilly USA, LLC | $64.96 | 2021-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $60.65 | 2021 | |
| Sunovion Pharmaceuticals INC. | $39.36 | 2021 | |
| Pfizer INC. | $36.89 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $28.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.51 | 2025 | Trintellix |
| Lundbeck LLC | $26.29 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $21.17 | 2025 | Fanapt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.50 | 2025 | |
| Indivior INC. | $20.31 | 2025 | Sublocade |
| Azurity Pharmaceuticals, INC. | $19.31 | 2023 | Horizant |
| Alkermes, INC. | $19.21 | 2025 | Vivitrol |
| Medtronic, INC. | $18.59 | 2025 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.78 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $17.40 | 2024 | Arexvy |
| Corium, LLC | $17.13 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $16.66 | 2024 | Austedo Xr |
| Hikma Pharmaceuticals USA | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Arbusto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.